Apvienotie Arābu Emirāti - angļu - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

city medical store - sole proprietorship l.l.c belgium - 15g tube - ointment - combination - skin-anti-infective skin preparations, skin-topical corticosteroids

Apvienotie Arābu Emirāti - angļu - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

city medical store - sole proprietorship l.l.c belgium - 15g tube - cream - combination - skin-anti-infective skin preparations, skin-topical corticosteroids

Uganda - angļu - National Drug Authority

msd (pty) limited sa - betamethasone /gentamicin sulphate - topical external ointments - 0.5mg/g+1.0mg/g

Apvienotie Arābu Emirāti - angļu - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

15g tube -

Kenija - angļu - Pharmacy and Poisons Board

msd (pty) ltd 117 16th road halfway house south africa - betamethasone dipropionate and gentamicin sulphate - cream - each 1g contains: 0.64 mg betamethasone… - combinations of weak corticosteroids antibiotics

Kenija - angļu - Pharmacy and Poisons Board

msd (pty) ltd 117 16th road halfway house south africa - betamethasone dipropionate & gentamicin sulphate - ointment - 0.640 mg/g betamethasone dipropionate and 1.000… - combinations of weak corticosteroids antibiotics

Namībija - angļu - Namibia Medicines Regulatory Council

msd (pty) ltd - betamethasone dipropionate, ; gentamicin sulphate - cream - betamethasone dipropionate 0,64 mg (equivalent to betamethasone 0.5mg) and ; gentamicin sulphate 0.17 mg/g (equivalent to 1 mg)

Namībija - angļu - Namibia Medicines Regulatory Council

msd (pty) ltd - betamethasone dipropionate, ; gentamicin sulphate - topical ointment - betamethasone dipropionate 0,64 mg (equivalent to betamethasone 0.5 mg) and ; gentamicin sulphate 0.17 mg/g (equivalent to 1mg)

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

progenics pharmaceuticals, inc. - iobenguane i-131 (unii: q461l7ak4r) (iobenguane i-131 - unii:q461l7ak4r) - azedra is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. none. risk summary based on its mechanism of action, azedra can cause fetal harm [see clinical pharmacology (12.1)] . there are no available data on azedra use in pregnant women. no animal studies using iobenguane i 131 have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, all radiopharmaceuticals, including azedra, have the potential to cause fetal harm. advise pregnant women of the risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary there are no data on the presence of iobenguane i 131 in human milk or its effects on the breastfed infant or milk production. no lactatio

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

progenics pharmaceuticals, inc. - piflufolastat f-18 (unii: 3934ef02t7) (piflufolastat f-18 - unii:3934ef02t7) - pylarify is indicated for positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer: - with suspected metastasis who are candidates for initial definitive therapy. - with suspected recurrence based on elevated serum prostate-specific antigen (psa) level. none. risk summary pylarify is not indicated for use in females. there is no information on the risk of adverse developmental outcomes in pregnant women or animals with the use of piflufolastat f 18. all radiopharmaceuticals, including pylarify, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. risk summary pylarify is not indicated for use in females. there is no information on the presence of piflufolastat f 18 in human milk, the effect on the breastfed infant, or the effect on milk production. the safety and effectiveness of pylarify in pediatric patients have not been established. of the 593 patients in completed clinical studies of pylarify, 355 (60%) were ≥65 years old, while 76 (12.8%) were ≥75 years old. the efficacy and safety of pylarify appear similar in adult and geriatric patients with prostate cancer, although the number of patients in the trials was not large enough to allow definitive comparison.